Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | XB2001 |
| Trade Name | |
| Synonyms | XB-2001|XB 2001|Vilamakitug |
| Drug Descriptions |
XB2001 is a monoclonal antibody that targets interleukin-1 alpha (IL1a), potentially resulting in decreased angiogenesis and reduced tumor formation (Ann Oncol (2024) 35 (suppl_1): S26, NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | 2458202-06-5 |
| NCIT ID | C180521 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Trifluridine-tipiracil hydrochloride + XB2001 | Bevacizumab Trifluridine-tipiracil hydrochloride XB2001 | 0 | 0 |
| Fluorouracil + Irinotecan + Leucovorin + XB2001 | Fluorouracil Irinotecan Leucovorin XB2001 | 0 | 1 |
| Trifluridine-tipiracil hydrochloride + XB2001 | Trifluridine-tipiracil hydrochloride XB2001 | 0 | 1 |
| XB2001 | XB2001 | 0 | 0 |